|
1
|
Walter RB, Othus M, Burnett AK, Löwenberg
B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T,
Evans A, et al: Resistance prediction in AML: Analysis of 4601
patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer
Center. Leukemia. 29:312–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramos NR, Mo CC, Karp JE and Hourigan CS:
Current approaches in the treatment of relapsed and refractory
acute myeloid leukemia. J Clin Med. 4:665–695. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Li H, Yu JP, Wang SE and Ren XB:
Role of SOCS1 in tumor progression and therapeutic application. Int
J Cancer. 130:1971–1980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trengove MC and Ward AC: SOCS proteins in
development and disease. Am J Clin Exp Immunol. 2:1–29.
2013.PubMed/NCBI
|
|
5
|
Skjesol A, Liebe T, Iliev DB, Thomassen
EI, Tollersrud LG, Sobhkhez M, Lindenskov Joensen L, Secombes CJ
and Jørgensen JB: Functional conservation of suppressors of
cytokine signaling proteins between teleosts and mammals: Atlantic
salmon SOCS1 binds to JAK/STAT family members and suppresses type I
and II IFN signaling. Dev Comp Immunol. 45:177–189. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lesinski GB, Zimmerer JM, Kreiner M,
Trefry J, Bill MA, Young GS, Becknell B and Carson WE III:
Modulation of SOCS protein expression influences the interferon
responsiveness of human melanoma cells. BMC Cancer. 10:1422010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beaurivage C, Champagne A, Tobelaim WS,
Pomerleau V, Menendez A and Saucier C: SOCS1 in cancer: An oncogene
and a tumor suppressor. Cytokine. 82:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CY, Tsay W, Tang JL, Shen HL, Lin SW,
Huang SY, Yao M, Chen YC, Shen MC, Wang CH and Tien HF:
SOCS1 methylation in patients with newly diagnosed acute
myeloid leukemia. Genes Chromosomes Cancer. 37:300–305. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu PY, Yeh CM, Hsu NC, Chang YS, Chang JG
and Yeh KT: Epigenetic alteration of the SOCS1 gene in
hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
|
|
11
|
Sobti RC, Singh N, Hussain S, Suri V,
Nijhawan R, Bharti AC, Bharadwaj M and Das BC: Aberrant promoter
methylation and loss of suppressor of cytokine signalling-1 gene
expression in the development of uterine cervical carcinogenesis.
Cell Oncol. 34:533–543. 2011. View Article : Google Scholar
|
|
12
|
Hussain S, Singh N, Salam I, Bandil K,
Yuvaraj M, Akbar Bhat M, Muzaffar Mir M, Siddiqi MA, Sobti RC,
Bharadwaj M, et al: Methylation-mediated gene silencing of
suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal
squamous cell carcinoma patients of Kashmir valley. J Recept Signal
Transduct Res. 31:147–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sakamoto LH, DE Camargo B, Cajaiba M,
Soares FA and Vettore AL: MT1G hypermethylation: A potential
prognostic marker for hepatoblastoma. Pediatr Res. 67:387–393.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu
H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in
breast cancer by targeting the suppressor of cytokine signaling 1
gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Babar IA, Cheng CJ, Booth CJ, Liang X,
Weidhaas JB, Saltzman WM and Slack FJ: Nanoparticle-based therapy
in an in vivo microRNA-155 (miR-155)-dependent mouse model of
lymphoma. Proc Natl Acad Sci USA. 109:E1695–E1704. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobayashi N, Uemura H, Nagahama K, Okudela
K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, et al:
Identification of miR-30d as a novel prognostic maker of prostate
cancer. Oncotarget. 3:1455–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park Y, Shon SK, Kim A, Kim KI, Yang Y,
Cho DH, Lee MS and Lim JS: SOCS1 induced by NDRG2 expression
negatively regulates STAT3 activation in breast cancer cells.
Biochem Biophys Res Commun. 363:361–367. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwahori K, Serada S, Fujimoto M, Ripley B,
Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto
T and Naka T: SOCS-1 gene delivery cooperates with cisplatin plus
pemetrexed to exhibit preclinical antitumor activity against
malignant pleural mesothelioma. Int J Cancer. 132:459–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doti N, Scognamiglio PL, Madonna S,
Scarponi C, Ruvo M, Perretta G, Albanesi C and Marasco D: New
mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1
through focused peptide libraries. Biochem J. 443:231–240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiong H, Du W, Zhang YJ, Hong J, Su WY,
Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone
deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing
the promoter-associated histone acetylation of SOCS1 and SOCS3 in
human colorectal cancer cells. Mol Carcinog. 51:174–184. 2012.
View Article : Google Scholar : PubMed/NCBI
|
